ロード中...
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/ https://ncbi.nlm.nih.gov/pubmed/20694077 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|